ADCY5 Gene

ADCY5 Gene

Introduction

The ADCY5 gene (Adenylate Cyclase 5) encodes adenylate cyclase 5 (AC5), a membrane-bound enzyme that catalyzes the conversion of ATP to cyclic AMP (cAMP). AC5 is one of ten mammalian adenylate cyclase isoforms and is particularly abundant in the striatum and other brain regions involved in motor control and reward processing.^{[@terminion1999]} This enzyme serves as a critical downstream effector of G protein-coupled receptors (GPCRs), particularly those coupled to Galphas proteins, including dopamine D1 receptors, adenosine A2A receptors, and beta-adrenergic receptors.^[@han2002]

ADCY5 Gene

Introduction

The ADCY5 gene (Adenylate Cyclase 5) encodes adenylate cyclase 5 (AC5), a membrane-bound enzyme that catalyzes the conversion of ATP to cyclic AMP (cAMP). AC5 is one of ten mammalian adenylate cyclase isoforms and is particularly abundant in the striatum and other brain regions involved in motor control and reward processing.^{[@terminion1999]} This enzyme serves as a critical downstream effector of G protein-coupled receptors (GPCRs), particularly those coupled to Galphas proteins, including dopamine D1 receptors, adenosine A2A receptors, and beta-adrenergic receptors.^[@han2002]

ADCY5 plays essential roles in basal ganglia function, integrating signals from multiple neurotransmitters to regulate motor activity, motor learning, and habit formation. Dysregulation of AC5-mediated cAMP signaling has been implicated in several neurodegenerative diseases, most notably [Parkinson's disease](/diseases/parkinsons-disease) and [Huntington's disease](/diseases/huntingtons-disease), as well as in familial movement disorders caused by ADCY5 mutations.^{[@watowich1999]}

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">ADCY5 Gene Summary</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ADCY5</td></tr>
<tr><td><strong>Full Name</strong></td><td>Adenylate cyclase 5</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>3q21.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[112](https://www.ncbi.nlm.nih.gov/gene/112)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[600293](https://www.omim.org/entry/600293)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000108055</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[O76074](https://www.uniprot.org/uniprot/O76074)</td></tr>
<tr><td><strong>Protein Length</strong></td><td>1264 amino acids</td></tr>
<tr><td><strong>Expression</strong></td><td>Highest in striatum, nucleus accumbens, cortex</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>PD, HD, familial dyskinesia, chorea</td></tr>
</table>
</div>

Gene Structure and Evolution

Genomic Organization

The ADCY5 gene spans approximately 67 kb on chromosome 3q21.1 and consists of 34 exons. The gene follows a typical pattern of mammalian adenylate cyclases, with a modular structure encoding distinct functional domains.^{[@sad友谊2017]}

Evolution

ADCY5 belongs to the Class III adenylate cyclase family, which is conserved from bacteria to humans. The ten mammalian ADCY isoforms (ADCY1-10) arose through gene duplication events during vertebrate evolution. ADCY5 and ADCY6 form a closely related pair, sharing approximately 75% amino acid identity and similar expression patterns, particularly in neuronal tissues.^[@chen2000]

Protein Structure and Function

Catalytic Mechanism

Adenylate cyclase 5 is a large integral membrane protein (approximately 150 kDa) with a characteristic architecture consisting of:

The catalytic activity resides in the C1 and C2 domains, which form a dimer that constitutes the functional enzyme core. Each catalytic domain contributes distinct residues to the active site, with the C2 domain primarily responsible for ATP binding and the C1 domain providing catalytic residues that facilitate the cyclization reaction.^{[@terminion1999]}

Regulation

AC5 activity is tightly regulated through multiple mechanisms:

• G protein regulation: Activated by Gαs/Gαolf subunits; inhibited by Gαi/o subunits
• Forskolin sensitivity: AC5 is highly responsive to forskolin, a plant diterpene that directly activates adenylate cyclases
• Calmodulin binding: AC5 is unique among adenylate cyclases in being inhibited by calmodulin in a calcium-dependent manner
• PKA phosphorylation: Feedback inhibition via protein kinase A phosphorylation
• PKA anchoring: A-kinase anchoring proteins (AKAPs) localize AC5 to specific subcellular compartments

Substrate and Products

AC5 catalyzes the reaction:
ATP → cAMP + PPi (pyrophosphate)

This reaction produces the second messenger cAMP, which activates protein kinase A (PKA), Epac (Exchange protein activated by cAMP), and cyclic nucleotide-gated (CNG) ion channels.^[@han2002]

Expression Pattern

Brain Expression

ADCY5 exhibits a highly region-specific expression pattern within the central nervous system:

| Brain Region | Expression Level | Functional Significance |
|--------------|-------------------|-------------------------|
| Striatum (caudate, putamen) | Very High | Motor control, habit learning |
| Nucleus accumbens | High | Reward processing, motivation |
| Olfactory tubercle | High | Olfactory signaling |
| Cerebral cortex | Moderate | Cortical processing |
| Hippocampus | Moderate | Memory, plasticity |
| Substantia nigra (pars compacta) | Moderate | Dopaminergic signaling |
| Cerebellum | Low-Moderate | Motor coordination |

The striatal expression of ADCY5 is particularly prominent in medium spiny neurons (MSNs), which constitute approximately 95% of striatal neurons and are the primary projection neurons of the basal ganglia.^{[@watowich1999]}

Cellular Localization

Within neurons, AC5 is primarily localized to the plasma membrane of dendritic shafts and dendritic spines, positioning it to respond to neurotransmitter receptors at synaptic sites. This subcellular distribution enables efficient coupling between receptor activation and second messenger production.^{[@sad友谊2017]}

Peripheral Expression

ADCY5 is also expressed in several peripheral tissues, including:

• Adrenal gland
• Heart (particularly in cardiac myocytes)
• Pancreas
• Immune cells (T lymphocytes, macrophages)

Role in Neurotransmitter Signaling

Dopamine Signaling

ADCY5 is a primary effector of dopamine D1 receptor (D1R) signaling in the striatum. D1 receptors are coupled to Gαs/olf, and their activation directly stimulates AC5 activity, leading to increased cAMP production and PKA activation.^[@chen2000]

This signaling cascade is critical for:

• Motor initiation and execution
• Reward learning and reinforcement
• Motor skill acquisition
• Habit formation

Adenosine Signaling

Adenosine A2A receptors, which are highly enriched in striatal projection neurons (particularly in indirect pathway MSNs), also couple to Gαs and stimulate AC5. This creates an important interaction between dopaminergic and adenosine signaling in the basal ganglia.^[@han2002]

A2A receptor antagonists (such as caffeine) produce their motor-activating effects partly through disinhibition of AC5 activity in striatal neurons.

Other Neurotransmitter Systems

ADCY5 responds to multiple neurotransmitters and neuromodulators:

• β-adrenergic receptors (norepinephrine)
• Serotonin (5-HT4, 5-HT6, 5-HT7 receptors)
• Histamine (H2 receptors)
• Glutamate (metabotropic glutamate receptors)
• Opioid receptors (μ and δ)

Disease Associations

Familial Dyskinesia with Facial Myokymia (FDFM)

Clinical Features:

• Autosomal dominant inheritance
• Childhood-onset choreiform movements
• Facial myokymia (rippling facial muscle contractions)
• Variable expressivity
• Often non-progressive

• Caused by heterozygous missense mutations in ADCY5
• Most common mutation: p.R218Q and p.R418Q
• Mutations cluster in the catalytic domains

• Mutations cause constitutive (ligand-independent) activation of AC5
• Leads to excessive cAMP production in neurons
• Disrupts normal basal ganglia circuit function
• Particularly affects striatal output pathways^{[@terminion1999]}

Parkinson's Disease

ADCY5 plays several roles in [Parkinson's disease](/diseases/parkinsons-disease) pathophysiology:

• Age at onset of PD
• Response to dopaminergic therapy
• Risk of developing dyskinesias

Huntington's Disease

In [Huntington's disease](/diseases/huntingtons-disease), AC5 function is altered in striatal neurons:

• cAMP signaling deficits: Reduced AC5 activity in medium spiny neurons
• D1R coupling: Impaired D1R-AC5 signaling contributes to motor dysfunction
• Energy metabolism: cAMP signaling is linked to mitochondrial function, which is disrupted in HD

Other Movement Disorders

• Chorea-acanthocytosis: AC5 dysregulation contributes to hyperkinetic movements
• Myoclonus-dystonia: Some cases involve cAMP signaling alterations
• Ataxia: Cerebellar AC5 may contribute to ataxic disorders

Therapeutic Targeting

Strategies for Targeting AC5

| Approach | Status | Description | Clinical Context |
|----------|--------|-------------|------------------|
| AC5 inhibitors | Preclinical | Small molecules targeting AC5 catalytic activity | Levodopa-induced dyskinesia |
| AC5 activators | Preclinical | Positive modulators of AC5 | Neuroprotection in PD |
| Gene therapy | Preclinical | AAV-mediated AC5 modulators | PD, HD |
| Allosteric modulators | Preclinical | Target specific conformational states | Selective targeting |
| AKAP disruptors | Preclinical | Disrupt AC5-AKAP interactions | Subunit-selective effects |

Current Research Directions

Clinical Considerations

• AC5 modulators must cross the blood-brain barrier
• Selectivity for AC5 vs. other adenylate cyclase isoforms is crucial
• Timing of intervention may be important (preventive vs. symptomatic)
• Monitoring cAMP levels in target tissues may serve as a biomarker

Animal Models

Genetic Models

• ADCY5 knockout mice: Viable but show reduced cAMP responses to dopamine
• ADCY5 conditional knockouts: Brain-specific deletion
• Transgenic mice: AC5 overexpression in striatum
• Human mutation knock-in: Mice carrying p.R418Q (familial dyskinesia mutation)

Behavioral Phenotypes

• Motor coordination deficits in rotorod testing
• Altered response to dopaminergic drugs
• Changes in locomotor activity
• Impaired motor learning

Pharmacological Models

• Forskolin administration to increase cAMP
• AC5-selective inhibitors
• D1R/D2R agonists and antagonists

Research Directions and Open Questions

Key Unresolved Questions

Emerging Research Areas

• Single-cell sequencing to define AC5-expressing neuronal subtypes
• Optogenetic control of cAMP dynamics
• Real-time cAMP imaging in vivo
• Protein-protein interaction mapping for AC5 signaling complexes

Cross-Links

Related Pages

• [Parkinson's Disease](/diseases/parkinsons-disease) - Primary disease association
• [Huntington's Disease](/diseases/huntingtons-disease) - Disease association
• [Dopamine D1 Receptor](/proteins/drd1-protein) - Primary upstream regulator
• [Adenosine A2A Receptor](/proteins/adora2a-protein) - Synergistic signaling
• [cAMP Signaling Pathway](/mechanisms/camp-dependent-signaling) - Downstream pathway
• [Striatum](/brain-regions/striatum) - Primary expression site
• [Basal Ganglia](/brain-regions/basal-ganglia) - Circuit function
• [Medium Spiny Neurons](/cell-types/medium-spiny-neurons) - Key cell type
• [Levodopa-Induced Dyskinesia](/mechanisms/levodopa-induced-dyskinesia) - Treatment complication

Related Genes

• [ADCY1](/genes/adcy1) - Neuronal isoform
• [ADCY2](/genes/adcy2) - Neuronal isoform
• [ADCY6](/genes/adcy6) - Closely related isoform
• [ADCY7](/genes/adcy7) - Immune-enriched isoform
• [ADCY9](/genes/adcy9) - Brain isoform
• [GNAO1](/genes/gnao1) - Gαo subunit, interacts with AC5
• [GNAS](/genes/gnas) - Gαs subunit, activates AC5
• [PDE1A](/genes/pde1a) - cAMP degradation
• [PDE4B](/genes/pde4b) - cAMP degradation

Brain Atlas Resources

• [Allen Human Brain Atlas](https://human.brain-map.org/) — gene expression data
• [BrainSpan Atlas](https://brainspan.org/) — developmental transcriptome
• [Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — mouse brain gene expression

References

Pathway Diagram

The following diagram shows the key molecular relationships involving ADCY5 Gene discovered through SciDEX knowledge graph analysis: